{"filing":{"accession_number":"0001104659-26-078023","cik":"0000744218","ticker":"CLDX","company_name":"Celldex Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-26","report_date":null,"primary_document":"tm2619009d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/744218/000110465926078023/tm2619009d1_8k.htm"},"events":[{"id":14128,"run_id":12566,"accession_number":"0001104659-26-078023","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"Celldex held its Annual Meeting of Stockholders on June 25, 2026, with shareholders voting on four proposals: election of nine directors, ratification of PricewaterhouseCoopers LLP as auditor, approval of an amendment to the 2021 Omnibus Equity Incentive Plan increasing available shares by 3.4 million, and advisory approval of named executive officer compensation. All proposals received tabulated voting results.","company_name":"Celldex Therapeutics, Inc.","ticker":"CLDX","filing_date":"2026-06-26","form":"8-K","submitted_at":null,"items":[{"id":11472,"accession_number":"0001104659-26-078023","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The disclosure centers on stockholder approval of an amendment to the 2021 Omnibus Equity Incentive Plan, increasing available shares by 3,400,000 and clarifying tax withholding provisions. This is a compensatory arrangement amendment requiring shareholder approval under Item 5.02(e), affecting the equity incentive framework available to officers and directors.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-26T12:44:38.114973+00:00","company_name":"","ticker":null,"filing_date":""},{"id":11473,"accession_number":"0001104659-26-078023","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear disclosure of shareholder voting results from Celldex's June 25, 2026 Annual Meeting, covering four proposals: election of nine directors, ratification of PricewaterhouseCoopers LLP as auditor, approval of an amendment to the 2021 Omnibus Equity Incentive Plan increasing shares by 3.4 million, and advisory approval of named executive officer compensation. The tabulated vote counts for each proposal are the hallmark of Item 5.07 disclosure and are material to investors assessing board composition, auditor selection, equity dilution, and executive compensation governance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-26T12:44:38.114973+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":11472,"accession_number":"0001104659-26-078023","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The disclosure centers on stockholder approval of an amendment to the 2021 Omnibus Equity Incentive Plan, increasing available shares by 3,400,000 and clarifying tax withholding provisions. This is a compensatory arrangement amendment requiring shareholder approval under Item 5.02(e), affecting the equity incentive framework available to officers and directors.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-26T12:44:38.114973+00:00","company_name":"Celldex Therapeutics, Inc.","ticker":"CLDX","filing_date":"2026-06-26"},{"id":11473,"accession_number":"0001104659-26-078023","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear disclosure of shareholder voting results from Celldex's June 25, 2026 Annual Meeting, covering four proposals: election of nine directors, ratification of PricewaterhouseCoopers LLP as auditor, approval of an amendment to the 2021 Omnibus Equity Incentive Plan increasing shares by 3.4 million, and advisory approval of named executive officer compensation. The tabulated vote counts for each proposal are the hallmark of Item 5.07 disclosure and are material to investors assessing board composition, auditor selection, equity dilution, and executive compensation governance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-26T12:44:38.114973+00:00","company_name":"Celldex Therapeutics, Inc.","ticker":"CLDX","filing_date":"2026-06-26"}]}